FR7693M - - Google Patents

Info

Publication number
FR7693M
FR7693M FR149924A FR149924A FR7693M FR 7693 M FR7693 M FR 7693M FR 149924 A FR149924 A FR 149924A FR 149924 A FR149924 A FR 149924A FR 7693 M FR7693 M FR 7693M
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR149924A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR7693M publication Critical patent/FR7693M/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
FR149924A 1967-08-10 1968-04-29 Expired FR7693M (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65960667A 1967-08-10 1967-08-10

Publications (1)

Publication Number Publication Date
FR7693M true FR7693M (fr) 1970-02-23

Family

ID=24646046

Family Applications (1)

Application Number Title Priority Date Filing Date
FR149924A Expired FR7693M (fr) 1967-08-10 1968-04-29

Country Status (9)

Country Link
US (1) US3642816A (fr)
JP (3) JPS509797B1 (fr)
BE (1) BE714439A (fr)
CH (1) CH507945A (fr)
DE (1) DE1770303A1 (fr)
FR (1) FR7693M (fr)
GB (1) GB1225664A (fr)
NL (1) NL6806044A (fr)
SE (1) SE355018B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224335A (en) * 1967-08-10 1980-09-23 Sterling Drug Inc. Tetrahydrocarbazoles and their use
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
GB1260768A (en) * 1969-08-28 1972-01-19 Pfizer N-alkyl-tetrahydrocarbazoles
US3920694A (en) * 1974-06-03 1975-11-18 Warner Lambert Co 4-hydroxy-9-methyl-4-vinyl-1,2,3,4-tetrahydrocarbazole
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
DE3631824A1 (de) * 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
EP0603432B1 (fr) * 1992-12-18 1998-10-21 Smithkline Beecham Plc Dérivés du tétrahydrocarbazole pour la préparation de médicaments pour traiter des maladies où on agoniste de la 5-HT1 est indiqué
DE69610793T2 (de) * 1995-06-23 2001-05-03 Lilly Co Eli 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists

Also Published As

Publication number Publication date
CH507945A (de) 1971-05-31
JPS5235669B1 (fr) 1977-09-10
GB1225664A (fr) 1971-03-17
JPS5328915B1 (fr) 1978-08-17
US3642816A (en) 1972-02-15
JPS509797B1 (fr) 1975-04-16
BE714439A (fr) 1968-10-30
SE355018B (fr) 1973-04-02
DE1770303A1 (de) 1971-10-07
NL6806044A (fr) 1969-02-12

Similar Documents

Publication Publication Date Title
FR7693M (fr)
BE711138A (fr)
BE711384A (fr)
BE711505A (fr)
BE711283A (fr)
BE711128A (fr)
BE710906A (fr)
BE710863A (fr)
BE710762A (fr)
BE710615A (fr)
BE710435A (fr)
BE710377A (fr)
BE710371A (fr)
BE709817A (fr)
BE709769A (fr)
BE709764A (fr)
BE709494A (fr)
BE709431A (fr)
BE708875A (fr)
BE708872A (fr)
BE708629A (fr)
BE707745A (fr)
BE707701A (fr)
BE704412A (fr)
BE703950A (fr)

Legal Events

Date Code Title Description
ST Notification of lapse
ST Notification of lapse